Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2013 Financial Results
March 26 2014 - 7:00AM
Marketwired
Titan Pharmaceuticals Schedules Conference Call to Review Fourth
Quarter and Full Year 2013 Financial Results
SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 26, 2014) - Titan
Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will
host a live conference call at 10 a.m. PT / 1 p.m. ET on Tuesday,
April 1, 2014 to discuss the company's financial results as of
December 31, 2013. The call will be hosted by Sunil Bhonsle,
president; Katherine Glassman-Beebe, Ph.D., executive vice
president and chief development officer; Brian Crowley, vice
president of finance, and Marc Rubin, M.D., executive chairman.
Highlights of the fourth quarter and full year financial results
will be included in a press release to be issued prior to the
call.
The live webcast of the call may be accessed by visiting the
Titan website at www.titanpharm.com. The call can also be accessed
by dialing (888) 221-3887, Participant Code 3001910 five minutes
prior to the start time. A replay of the call will be
available on the company website approximately two hours after
completion of the call and will be archived for two weeks.
About Titan Pharmaceuticals Titan Pharmaceuticals Inc. (OTCBB:
TTNP), based in South San Francisco, CA, is a specialty
pharmaceutical company developing proprietary therapeutics
primarily for the treatment of serious medical disorders. The
company's lead product candidate is Probuphine®, a novel and
long-acting formulation of buprenorphine for the long-term
maintenance treatment of opioid dependence. Probuphine employs
Titan's proprietary drug delivery system ProNeura™, which is
capable of delivering sustained, consistent levels of medication
for six months or longer. Titan has granted North American
commercial rights for Probuphine to Braeburn Pharmaceuticals. If
approved, Probuphine would be the first and only commercialized
treatment of opioid dependence to provide continuous,
round-the-clock blood levels of buprenorphine for six months. The
ProNeura technology has the potential to be used in developing
products for treating other chronic conditions, such as Parkinson's
disease, where maintaining consistent blood levels of a dopamine
agonist may benefit the patient and improve medical outcomes. For
more information about Titan, please visit www.titanpharm.com.
The press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, any statements relating to our
product development programs and any other statements that are not
historical facts. Such statements involve risks and uncertainties
that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause
actual results to differ materially from management's current
expectations include those risks and uncertainties relating to the
regulatory approval process, the development, testing, production
and marketing of our drug candidates, patent and intellectual
property matters and strategic agreements and
relationships. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
CONTACT: For Investors: Titan Pharmaceuticals, Inc. Sunil
Bhonsle (650) 244-4990 President For Media: Susan Thomas (619)
540-9195 stcommunications@aol.com
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Apr 2023 to Apr 2024